The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials

L E Kristensen; A K Jakobsen; E M Bartels; P Geborek; H Bliddal; T Saxne; B Danneskiold-Samsøe; R Christensen

doi:10.3109/03009742.2010.491834

The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials

L E Kristensen, A K Jakobsen, E M Bartels, P Geborek, H Bliddal, T Saxne, B Danneskiold-Samsøe, R Christensen

The Parker Institute

23 Citations (Scopus)

Abstract

To evaluate the number needed to treat (NNT) and the number needed to harm (NNH) of the second-generation biologics abatacept, certolizumab, golimumab, rituximab, and tocilizumab in patients with established rheumatoid arthritis (RA) taking concomitant methotrexate (MTX).

Original language	English
Journal	Scandinavian Journal of Rheumatology
Volume	40
Issue number	1
Pages (from-to)	1-7
Number of pages	7
ISSN	0300-9742
DOIs	https://doi.org/10.3109/03009742.2010.491834
Publication status	Published - 2011

Keywords

Adult
Antibodies, Monoclonal
Antirheumatic Agents
Arthritis, Rheumatoid
Biological Agents
Databases, Bibliographic
Double-Blind Method
Female
Humans
Male
Middle Aged
Randomized Controlled Trials as Topic
Research Design
Sample Size

Access to Document

10.3109/03009742.2010.491834

Cite this

Kristensen, L. E., Jakobsen, A. K., Bartels, E. M., Geborek, P., Bliddal, H., Saxne, T., Danneskiold-Samsøe, B., & Christensen, R. (2011). The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials. Scandinavian Journal of Rheumatology, 40(1), 1-7. https://doi.org/10.3109/03009742.2010.491834

The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials. / Kristensen, L E; Jakobsen, A K; Bartels, E M et al.
In: Scandinavian Journal of Rheumatology, Vol. 40, No. 1, 2011, p. 1-7.

Research output: Contribution to journal › Journal article › Research › peer-review

Kristensen, LE, Jakobsen, AK, Bartels, EM, Geborek, P, Bliddal, H, Saxne, T, Danneskiold-Samsøe, B & Christensen, R 2011, 'The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials', Scandinavian Journal of Rheumatology, vol. 40, no. 1, pp. 1-7. https://doi.org/10.3109/03009742.2010.491834

@article{d82227d01a5d4dffa00b120b5a4d373b,

title = "The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials",

abstract = "To evaluate the number needed to treat (NNT) and the number needed to harm (NNH) of the second-generation biologics abatacept, certolizumab, golimumab, rituximab, and tocilizumab in patients with established rheumatoid arthritis (RA) taking concomitant methotrexate (MTX).",

keywords = "Adult, Antibodies, Monoclonal, Antirheumatic Agents, Arthritis, Rheumatoid, Biological Agents, Databases, Bibliographic, Double-Blind Method, Female, Humans, Male, Middle Aged, Randomized Controlled Trials as Topic, Research Design, Sample Size",

author = "Kristensen, \{L E\} and Jakobsen, \{A K\} and Bartels, \{E M\} and P Geborek and H Bliddal and T Saxne and B Danneskiold-Sams{\o}e and R Christensen",

year = "2011",

doi = "10.3109/03009742.2010.491834",

language = "English",

volume = "40",

pages = "1--7",

journal = "Scandinavian Journal of Rheumatology",

issn = "0300-9742",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

TY - JOUR

T1 - The number needed to treat for second-generation biologics when treating established rheumatoid arthritis

T2 - a systematic quantitative review of randomized controlled trials

AU - Kristensen, L E

AU - Jakobsen, A K

AU - Bartels, E M

AU - Geborek, P

AU - Bliddal, H

AU - Saxne, T

AU - Danneskiold-Samsøe, B

AU - Christensen, R

PY - 2011

Y1 - 2011

N2 - To evaluate the number needed to treat (NNT) and the number needed to harm (NNH) of the second-generation biologics abatacept, certolizumab, golimumab, rituximab, and tocilizumab in patients with established rheumatoid arthritis (RA) taking concomitant methotrexate (MTX).

AB - To evaluate the number needed to treat (NNT) and the number needed to harm (NNH) of the second-generation biologics abatacept, certolizumab, golimumab, rituximab, and tocilizumab in patients with established rheumatoid arthritis (RA) taking concomitant methotrexate (MTX).

KW - Adult

KW - Antibodies, Monoclonal

KW - Antirheumatic Agents

KW - Arthritis, Rheumatoid

KW - Biological Agents

KW - Databases, Bibliographic

KW - Double-Blind Method

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Randomized Controlled Trials as Topic

KW - Research Design

KW - Sample Size

UR - https://www.scopus.com/pages/publications/79952264014

U2 - 10.3109/03009742.2010.491834

DO - 10.3109/03009742.2010.491834

M3 - Journal article

C2 - 20950126

SN - 0300-9742

VL - 40

SP - 1

EP - 7

JO - Scandinavian Journal of Rheumatology

JF - Scandinavian Journal of Rheumatology

IS - 1

ER -

The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this